A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity.
OBJECTIVE: This post hoc analysis assessed psychiatric changes with tirzepatide in adults with obesity, without known major psychopathology, from SURMOUNT-1, SURMOUNT-2, and SURMOUNT-3. METHODS: In participants (N = 4056) treated with tirzepatide (5/…
BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists are a key pharmacological target in obesity management, associated with sustained weight loss and broader metabolic benefits beyond glycaemic control. OBJECTIVE: To analyse the characteris…
BACKGROUND: This study evaluated the safety of compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) compared to non-compounded formulations using the U.S. FDA Adverse Event Reporting System (FAERS). RESEARCH DESIGN AND METHODS: A retrospe…
BACKGROUND: Tirzepatide, a dual GIP/GLP-1 receptor agonist, offers a novel cardiometabolic strategy beyond glycemic control with important implications for heart failure care. By producing potent, sustained weight reduction and favourable changes in…
BACKGROUND: Tirzepatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist, has demonstrated robust weight loss and glycemic benefits in randomized controlled trials. However, real-world data comparing its e…
AIMS: Evidence on cardiovascular/renal outcomes associated with GLP-1-based therapies in type 1 diabetes (T1D) is limited. We examined the effects of GLP-1-based therapy on major clinical outcomes and safety, including diabetic ketoacidosis (DKA) and…
A decline in mortality due to heart failure (HF) with reduced ejection fraction (HFrEF) has been attributed to effective guideline-directed medical therapies. But few effective therapies are available for HF with preserved ejection fraction (HFpEF),…
Anti-obesity drugs should be offered as initial treatment of overweight and obesity for adults with weight-related comorbidities and for those at high risk of complications, and as a component of first-line treatment for patients with obesity and ove…
PURPOSE OF REVIEW: To examine the role of pharmacologic obesity treatment in people with type 2 diabetes (T2D), with a focus on efficacy, safety, and clinical positioning in the context of T2D-specific metabolic and therapeutic challenges. RECENT FIN…
Numerous reports have documented the incidence of euglycemic ketoacidosis as a complication of sodium-glucose cotransporter-2 (SGLT-2) inhibitors. However, euglycemic ketoacidosis secondary to the use of glucose-dependent insulinotropic polypeptide (…
OBJECTIVE: Overweight and obesity are prevalent in type 1 diabetes and contribute to cardiovascular risk. Tirzepatide, a gastric inhibitory polypeptide and glucagon-like peptide 1 receptor coagonist, has not been studied in type 1 diabetes. RESEARCH…
The global increase in obesity highlights the need for accurate tools to assess body composition and monitor treatment efficacy. Traditional metrics, including body mass index and waist circumference, offer limited precision for fat quantification. I…
AIM: To evaluate the association between preconception glucagon-like peptide-1 receptor agonist (GLP-1RA)/tirzepatide use and the risk of gestational diabetes mellitus (GDM). METHODS: This retrospective cohort study (January 1, 2015-April 30, 2025) u…
IMPORTANCE: The association of bariatric surgery and newer glucagon-like peptide-1 receptor agonists (GLP-1RAs; semaglutide and tirzepatide) with body composition still lack evidence from clinical settings. OBJECTIVE: To examine temporal changes in f…
BACKGROUND: Cocaine use disorder (CUD) remains among the most treatment-resistant addictions, characterised by high relapse rates even following extended abstinence periods. Dopamine signalling in mesocorticolimbic circuits contributes to cocaine's r…
(), a novel highly potent GLP-1/GIP dual agonist, was engineered via computational alanine scanning and rational acylation design. Nonacylated() showed stable receptor binding and higher affinity than nonacylatedin molecular dynamics simulations and…
Objective Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has been shown to improve hepatic inflammation and steatosis in patients with type 2 diabetes. However, whether its…
BACKGROUND: Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, is increasingly used for obesity treatment, including in individuals without diabetes. Starvation ketoacidosis is a rare but se…
INTRODUCTION: Recent pharmacological options for weight management include the glucagon-like peptide 1 (GLP-1) receptor agonists semaglutide and liraglutide, and the glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist tirzepatide,…